Sarepta Therapeutics Inc. stock slid 6.4% Thursday, after a news report cast uncertainty over the path to regulatory approval for the company’s SRP-9001 gene therapy for a rare genetic disorder.
SRP-9001 is a treatment for Duchenne muscular dystrophy, or DMD, an inherited disorder of progressive muscular weakness that typically affects boys. Symptoms that appear in early childhood include frequent falls, difficulties getting up or running and learning disabilities, and patients have a life expectancy of about 27. About 20,000…
This post was originally published on Market Watch
